CLDX Executive VP & Cso Tibor Keler Buys 115,000 Shares

Insider Buying and Selling at Celldex Therapeutics, Inc.

Tibor Keler, the Executive Vice President and Chief Scientific Officer at Celldex Therapeutics, Inc. (NasdaqCM: CLDX), has acquired 115,000 shares on June 25, 2026. This purchase is valued at approximately $4.05 million based on a share price of $35.26 at the time of the transaction.

A Wave of Insider Transactions

Keler's purchase adds to a notable trend of insider buying on the same day. Other insiders also made significant acquisitions, including CEO Anthony Marucci, who bought 375,000 shares, and Freddy Jimenez, who purchased 93,000 shares. Additionally, Sarah Cavanaugh and Margo Heath-Chiozzi each bought 95,000 shares, while Harry Penner Jr. and Herbert Conrad each acquired 26,000 shares. This collective buying suggests a strong belief in the company's future prospects.

Stock Performance and Market Context

Celldex Therapeutics is currently trading well above its 52-week low of $22.1 and close to its 52-week high of $45.14. The stock was last seen at $35.26, which is below its 50-day moving average of $39.10 but above the 200-day average of $32.18. This positioning may indicate a favorable outlook as insiders increase their stakes.

Analysts Set New Price Targets

Analysts have a positive view on Celldex, with a consensus rating of "strong buy" and a mean price target of $59.07. Recent ratings include HC Wainwright & Co. reiterating a buy with a target of $64 on October 2, 2026, and Leerink Partners maintaining an outperform rating with a revised target of $88 on September 23, 2026. This analyst support reinforces the optimistic sentiment seen in insider transactions.

What Celldex Therapeutics, Inc. Does

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. Their innovative drug candidates aim to address conditions where existing treatments are inadequate, positioning the company for potential growth as it advances its clinical programs.

What's Ahead for Celldex Therapeutics, Inc.

Investors will be watching for the next earnings report scheduled for November 9, 2026. The recent insider purchases reflect confidence in the company's direction, but it's important to remember that these trades are based on past performance and may not indicate current holdings. As Celldex continues to develop its promising therapies, market watchers will be keen to see how these insider moves align with future developments.